BROOKLYN, N.Y.,, June 08, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc.(NASDAQ:AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the closing of a private placement financing resulting in gross proceeds of $5.0 million. Alexander Capital, LP acted as sole placement agent in the financing.
“We are very grateful for the continued support of our investors and thrilled that the financing was over-subscribed,” said Thijs Spoor, the President and CEO of AzurRx. “This financing allows us to continue the development of our MS1819 program for the treatment of exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis patients.”
The financing consisted of units sold at a price of $3.50 per unit, with each unit consisting of one share of common stock, one Series A Warrant to purchase 0.25 shares of common stock at $4.00 per share exercisable immediately through December 31, 2017, and one Series A-1 Warrant to purchase 0.75 shares of common stock at $5.50 per share exercisable beginning six months from the date of issuance through June 6, 2022. At closing, the Company issued an aggregate of 1,428,572 shares of common stock, Series A Warrants to purchase up to 357,143 shares of common stock, and Series A-1 Warrants to purchase up to 1,071,429 shares of common stock.
The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements. AzurRx has agreed to file one or more registration statements with the SEC registering the resale of the shares of common stock purchased in the private placement and the shares of common stock issuable upon exercise of the warrants.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.
About AzurRx BioPharma, Inc.:
AzurRx BioPharma, Inc. (NASDAQ:AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the Company's lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections. The Company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France. Additional information on the company can be found at www.azurrx.com.
